HIP1R与波形蛋白免疫组化预测IDH突变型胶质瘤的1p/19q状态
研究通过质谱蛋白质组学在35例新鲜冷冻和72例福尔马林固定石蜡包埋的IDH及1p/19q状态明确的肿瘤中发现生物标志物,并在两个独立验证队列(共77例少突胶质瘤IDH突变1p/19q共缺失和92例星形细胞瘤IDH突变)中进行免疫组化验证。结果显示HIP1R高表达和波形蛋白低表达见于少突胶质瘤,反之见于星形细胞瘤;盲法评估预测1p/19q状态的阳性预测值、阴性预测值和准确率在第一队列均为100%,第二队列分别为83%、100%和92%;联合核ATRX缺失标志可将敏感性提高至96%、特异性提高至100%。结论认为HIP1R、波形蛋白和ATRX免疫组化预测1p/19q状态具有100%特异性和95%敏感性,是简单廉价的分类方法。
要点
- HIP1R高表达和波形蛋白低表达见于少突胶质瘤IDH突变1p/19q共缺失,反之见于星形细胞瘤IDH突变。
- 盲法评估验证队列预测1p/19q状态:第一队列阳性预测值、阴性预测值和准确率均为100%,第二队列分别为83%、100%和92%。
- 核ATRX缺失作为星形细胞瘤标志可将敏感性提高至96%、特异性提高至100%。
核心结论
- HIP1R、波形蛋白和ATRX免疫组化预测1p/19q状态具有100%特异性和95%敏感性,是简单廉价的IDH突变型胶质瘤分类方法。
研究设计与样本
- 发现阶段采用基于质谱的蛋白质组学分析35例新鲜冷冻和72例福尔马林固定石蜡包埋的IDH及1p/19q状态明确的肿瘤。
- 验证阶段在两个独立队列(共77例少突胶质瘤IDH突变1p/19q共缺失和92例星形细胞瘤IDH突变)中进行免疫组化。
主要发现
- 少突胶质瘤中观察到HIP1R高表达和波形蛋白低表达,星形细胞瘤中为HIP1R低表达和波形蛋白高表达。
- FFPE发现系列35例的HIP1R和波形蛋白免疫组化表达证实了上述发现。
- 盲法评估验证队列预测1p/19q状态:第一队列阳性预测值、阴性预测值和准确率均为100%;第二队列阳性预测值83%、阴性预测值100%、准确率92%。
- 核ATRX缺失作为星形细胞瘤标志将敏感性提高至96%、特异性提高至100%。
关键数值与推荐
- HIP1R高表达和波形蛋白低表达对应少突胶质瘤IDH突变1p/19q共缺失。
- HIP1R低表达和波形蛋白高表达对应星形细胞瘤IDH突变。
- 核ATRX缺失作为星形细胞瘤标志,联合HIP1R和波形蛋白可将敏感性提高至96%、特异性提高至100%。
临床怎么用
- 作者认为HIP1R、波形蛋白和ATRX免疫组化预测1p/19q状态具有100%特异性和95%敏感性,构成简单廉价的IDH突变型胶质瘤分类方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IDH-mutant gliomas are separate based on the codeletion of the chromosomal arms 1p and 19q into oligodendrogliomas IDH-mutant 1p/19q-codeleted and astrocytomas IDH-mutant. While nuclear loss of ATRX expression excludes 1p/19q codeletion, its limited sensitivity prohibits to conclude on 1p/19q status in tumors with retained nuclear ATRX expression. METHODS: Employing mass spectrometry based proteomic analysis in a discovery series containing 35 fresh frozen and 72 formalin fixed and paraffin embedded tumors with established IDH and 1p/19q status, potential biomarkers were discovered. Subsequent validation immunohistochemistry was conducted on two independent series (together 77 oligodendrogliomas IDH-mutant 1p/19q-codeleted and 92 astrocytomas IDH-mutant). RESULTS: We detected highly specific protein patterns distinguishing oligodendroglioma and astrocytoma. In these patterns, high HIP1R and low vimentin levels were observed in oligodendroglioma while low HIP1R and high vimentin levels occurred in astrocytoma. Immunohistochemistry for HIP1R and vimentin expression in 35 cases from the FFPE discovery series confirmed these findings. Blinded evaluation of the validation cohorts predicted the 1p/19q status with a positive and negative predictive value as well as an accuracy of 100% in the first cohort and with a positive predictive value of 83%; negative predictive value of 100% and an accuracy of 92% in the second cohort. Nuclear ATRX loss as marker for astrocytoma increased the sensitivity to 96% and the specificity to 100%. CONCLUSIONS: We demonstrate that immunohistochemistry for HIP1R, vimentin, and ATRX predict 1p/19q status with 100% specificity and 95% sensitivity and therefore, constitutes a simple and inexpensive approach to the classification of IDH-mutant glioma.
引用
- Felix M, Friedel D, Jayavelu AK, et al. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Neuro Oncol. 2022. PMID: 35511748. doi:10.1093/neuonc/noac111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。